CN110192654A - Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation - Google Patents
Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation Download PDFInfo
- Publication number
- CN110192654A CN110192654A CN201910558717.0A CN201910558717A CN110192654A CN 110192654 A CN110192654 A CN 110192654A CN 201910558717 A CN201910558717 A CN 201910558717A CN 110192654 A CN110192654 A CN 110192654A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- liver
- drinking
- alcohol
- ymc1005
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 74
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 74
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 74
- 230000006378 damage Effects 0.000 title claims abstract description 21
- 230000035622 drinking Effects 0.000 title claims abstract description 20
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 208000014674 injury Diseases 0.000 title claims abstract description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- 239000012267 brine Substances 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 235000012027 fruit salads Nutrition 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008268 mayonnaise Substances 0.000 claims description 3
- 235000010746 mayonnaise Nutrition 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- 235000012033 vegetable salad Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 42
- 230000036541 health Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 235000019441 ethanol Nutrition 0.000 description 43
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 32
- 210000002966 serum Anatomy 0.000 description 23
- 230000001684 chronic effect Effects 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 16
- 229960003180 glutathione Drugs 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000011049 filling Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 231100000753 hepatic injury Toxicity 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 oxygen radical Chemical class 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000014898 transaminase activity proteins Human genes 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 235000020167 acidified milk Nutrition 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910017234 MnSO4 H2O Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008398 formation water Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation, belongs to the technical field of microorganism, and causing body discomfort and protection after drinking for alleviation, liver health has very extensive application prospect after drinking.
Description
Technical field
The invention belongs to the technical fields of microorganism, are related to one plant of lactobacillus plantarum that can alleviate body discomfort after drinking,
Alleviate the application in the food of body injury after drinking in preparation more particularly to lactobacillus plantarum LP45
Background technique
" lancet " report, the responsible drinking saying beneficial to body be completely it is worthless, moreover, drinking is the whole world
Lead to (15-49 years old) dead No.1 assailant of Lipid on Young-middle Male in range.Long-term alcohol will cause various body organs and cause to damage
Wound can cause mucosal lesion to cause gastric ulcer even bleeding crisis life, liver fat is caused to accumulate to form alcohol fatty
The diseases such as liver cause to damage to nervous system, induce peripheral neuropathy even cerebral cortical atrophy, attention occur and do not collect
In, memory loss phenomena such as.
Alcohol causes the main mechanism of body injury: (1) ethyl alcohol: damage stomach lining leads to gastrointestinal smooth muscle spasmus,
Vomiting centre is stimulated, is caused vomiting.Destroy mucous membrane system of defense, gastric acid secretion reduce, cause mucosal tissue oedema, erosion,
Bleeding, necrosis；Normal intestinal flora imbalance: intestinal microecology disorder, pathogenic bacteria undue growth, endotoxin increase, intestinal mucosa screen
Hinder miopragia, leads to diarrhea；(2) acetaldehyde: entering blood circulation, makes one to blush, dizziness, goes up painful, radiates, is thirsty；Across blood
Brain barrier, leads to brain damage；I grades of carcinogenic substances, lead to intestinal tract injury, hepar damnification.(3) it is logical endotoxin: to destroy gut barrier
Permeability enters liver by portal vein, causes hepatic injury (liver inflammation, fibrosis, liver cancer).(4) oxidative stress: ethyl alcohol acetaldehyde
A large amount of free radicals are generated in metabolic process, enterocyte is caused to damage, and cause inflammation, intestinal permeability to increase, intestinal mucosa screen
Hinder miopragia；Lead to Liver fatty deposition, causes fatty liver.
Summary of the invention
The object of the present invention is to provide the purposes of lactobacillus plantarum (lactobacillus plantarum) LP45 a kind of,
Merchant Codes lactobacillus plantarum LP45, the lactobacillus is on August 26th, 2013 in Chinese microorganism strain preservation conservator
Meeting common micro-organisms center has carried out preservation, and deposit number is CGMCC No.8072, biomaterial YMC1005, classification naming
Lactobacillus plantarum, preservation address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3.
Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation.
It will freeze in -80 DEG C of lactobacillus plantarum LP45 access MRS fluid nutrient medium, 37 DEG C of culture 18h are continuous living
Change three generations after, at 4 DEG C 6000rmp be centrifuged 10min, abandon supernatant, by thallus sterilizing brine three times after, resuspension
In physiological saline and adjust cell concentration 109CFU/ml obtains cell suspension, and preservation is stand-by in 4 DEG C of low temperature, by cell
Lactobacillus plantarum LP45 pulvis is prepared by freeze-drying in suspension.
The food is using one of oligofructose, lactitol, stachyose or any combination and lactobacillus plantarum
LP45 pulvis is mixed to get.
By lactobacillus plantarum LP45 pulvis, it is uniformly mixed with 100 grams of mayonnaise, is made as vegetable and fruit salad, controls it
Viable count reaches 109CFU/ml。
Acidified milk is made as using lactobacillus plantarum LP45 as fermentation strain.
The dosage form of the food is granule, pulvis or tablet.
The lactobacillus plantarum LP45 (YMC1005) has the following properties:
(1), there is acid resistance, well-grown in the environment of pH3.0；
(2), it can produce acetaldehyde dehydrogenase；
(3), there is oxidation resistance, reduce oxidative stress；
(4), it can produce γ-aminobutyric acid；
(5), blood ammonia can be inhibited to increase, is anti-oxidant, inhibit inflammatory factor, effective protection liver health after drinking.
The beneficial effects of the present invention are:
The purposes of lactobacillus plantarum of the invention, alleviation cause body uncomfortable after drinking and protection after drinking liver health have it is non-
Normal broad application prospect.Lactobacillus plantarum LP45 (YMC1005) of the invention has acid resistance, can produce acetaldehyde-dehydrogenase
Enzyme, the metabolite acetaldehyde of the efficient oxidation alcohol；It can produce SOD and GSH, improve antioxidant ability of organism, mitigate oxidation damage
Wound；Serum ALT and AST caused by alcohol increase and inhibiting effect；Liver MDA, which increases, caused by alcohol inhibiting effect,
And restore liver GSH and SOD activity；Serum endotoxin, which increases, caused by alcohol inhibiting effect；The liver caused by alcohol
The raising of the Cellular inflammatory factor has inhibiting effect；Mitigate liver fat bubble, mitigates inflammatory cell infiltration.The lactobacillus plantarum can be with
Hepar damnification caused by alcohol is effectively relieved.
Ethyl alcohol causes body uncomfortable and the principal element of hepar damnification includes four aspects: (1) in ethyl alcohol (2) acetaldehyde (3)
Toxin (4) oxidative stress；Lactobacillus plantarum LP45 (YMC1005) of the present invention can be directly against in above four factors, to alleviate
Alcoholic liver injury and after drinking a variety of malaise symptoms；LP45 first can be de- from the generation alcohol dehydrogenase in enteron aisle and acetaldehyde
Hydrogen enzyme mitigates its damage to body come the concentration of degrade Oxidation of Alcohol and acetaldehyde, in addition the antibacterial work of LP45 (YMC1005)
With, the proliferation of Escherichia coli in the enteron aisle as caused by ethyl alcohol, salmonella etc. can be inhibited, reduce endotoxic generation, protection
Gut barrier reduces endotoxin and enters the inflammatory reaction that blood causes body.LP45 (YMC1005) itself is in enteron aisle simultaneously
The glutathione peroxidase of generation, while body producing enzyme is stimulated, two aspect collective effects are drunk to be effective against for machine
Oxidative damage caused by body, and other bacterium are only through stimulation body itself producing enzyme, to reach oxidation resistant purpose.
Detailed description of the invention
Fig. 1 is the acid resistance schematic diagram of lactobacillus plantarum LP45 (YMC1005).
Fig. 2 is that lactobacillus plantarum LP45 (YMC1005) inhibits pathogenic bacteria ability schematic diagram.
Fig. 3 is that lactobacillus plantarum LP45 (YMC1005) produces acetaldehyde dehydrogenase ability schematic diagram.
Fig. 4 is that lactobacillus plantarum LP45 (YMC1005) produces GSH ability schematic diagram.
Fig. 5 is lactobacillus plantarum LP45 (YMC1005) tolerance H2O2Ability schematic diagram.
Fig. 6 is the influence that lactobacillus plantarum LP45 (YMC1005) changes AST in mice serum caused by Chronic Alcohol
Figure.
Fig. 7 is the influence that lactobacillus plantarum LP45 (YMC1005) changes ALT in mice serum caused by Chronic Alcohol
Figure.
Fig. 8 is the influence diagram that lactobacillus plantarum LP45 (YMC1005) changes mouse liver MDA caused by Chronic Alcohol.
Fig. 9 is the influence diagram that lactobacillus plantarum LP45 (YMC1005) changes mouse liver GSH caused by Chronic Alcohol.
Figure 10 is the influence that lactobacillus plantarum LP45 (YMC1005) changes mouse liver SOD caused by Chronic Alcohol
Figure.
Figure 11 is the influence that lactobacillus plantarum LP45 (YMC1005) causes that LPS changes in mice serum to Chronic Alcohol
Figure.
Figure 12 is the shadow that lactobacillus plantarum LP45 (YMC1005) changes TNF-α in mouse liver caused by Chronic Alcohol
Ring figure.
Figure 13 is the shadow that lactobacillus plantarum LP45 (YMC1005) changes IL-1 β in mouse liver caused by Chronic Alcohol
Ring figure.
Figure 14 is the shadow that lactobacillus plantarum LP45 (YMC1005) changes IL-6 in mouse liver caused by Chronic Alcohol
Ring figure.
Figure 15 is influence of the lactobacillus plantarum LP45 (YMC1005) to Chronic Alcohol exposure mouse liver Histopathological lesions
Scheme, wherein A: blank group；B alcohol group；C alcohol+medicine group；E alcohol+LP45 group.
Figure 16 is that Application Example 3 is fermented the tart flavour of emulsion formulation, fragrance, viscosity, plumpness, sophistication, grease sense, suitable
Slippery figure.
Figure 17 is the acid resistance figure of lactobacillus plantarum LP45 (YMC1005).
Specific embodiment
The present invention is further explained in the light of specific embodiments.
The detailed description of the property of lactobacillus plantarum (lactobacillus plantarum) LP45 (YMC1005):
1, there is acid resistance, can grow at a low ph
The activated bacterial strain, 10% is inoculated in the modified MRS culture medium of pH3.0, in 37 DEG C, respectively at 0h,
2h, 4h record viable count, verify its acid resistance.
2, it can produce acetaldehyde dehydrogenase
The lactobacillus plantarum LP45 bacterium powder is dissolved in physiological saline, after centrifuge washing, is resuspended in physiological saline, makes
With Ultrasonic Cell Disruptor, it is crushed thallus, after the operation of acetaldehyde-dehydrogenase enzyme reagent kit, is examined at the wavelength of 450nm using microplate reader
Light absorption value is surveyed, the bacterial strain is calculated and produces acetaldehyde dehydrogenase ability.
3, there is oxidation resistance, mitigate oxidative stress
The lactobacillus plantarum LP45 bacterium powder is dissolved in physiological saline, after centrifuge washing, is resuspended in physiological saline, makes
With super refreshing broken instrument, be crushed thallus, by broken thallus according to the operation of GSH, SOD kit after, using microplate reader respectively at
Light absorption value is detected at the wavelength of 420nm, 450nm, is calculated the bacterial strain and is produced GSH, SOD ability.
4, blood ammonia can be inhibited to increase, is anti-oxidant, reduce serum endotoxin, inhibit inflammatory factor, effective protection liver is strong
Health
After intragastric administration on mice alcohol, lactobacillus plantarum of the present invention, can be with compared with blank group, model group and medicine group
The raising of ALT, AST in mice serum is effectively reduced；MDA concentration in mouse liver can be effectively reduced, and restore liver GSH
Content and SOD activity, effectively inhibit liver oxidative damage caused by Chronic Alcohol；LPS content in mice serum is effectively reduced
It increases, protection intestinal microecology balance protects gut muco-membranous barrier；Effectively inhibit inflammatory factor in liver caused by Chronic Alcohol
The raising of TNF-α, IL-6, IL-1 β content prevents liver inflammation caused by alcohol from reacting；Hepatic pathology damage, table is effectively relieved
It is now reduced for fat bubble, mild inflammatory cell infiltration, karyopycnosis is slight.
One, embodiment
1, the activation of lactobacillus plantarum LP45 (YMC1005) strain
It will freeze in -80 DEG C of lactobacillus plantarum LP45 access MRS fluid nutrient medium, 37 DEG C of culture 18h are continuous living
Change three generations after, at 4 DEG C 6000rmp be centrifuged 10min, abandon supernatant, by thallus sterilizing brine three times after, resuspension
In physiological saline and cell concentration, as cell suspension are adjusted, preservation is stand-by in 4 DEG C of low temperature.
2, inhibit pathogenic bacteria growth
The lactobacillus plantarum LP45 (YMC1005) is seeded in modified MRS culture medium with 3% inoculum concentration, is cultivated
For 24 hours, bacterium solution 8000rpm is centrifuged 2min, collects culture supernatant, part supernatant pH is adjusted between 5.5-5.6, with 0.22
μm membrane filtration degerming, it is spare.The preparation method of modified MRS are as follows: glucose: 20g, peptone: 10g, powdered beef: 6.5g,
Yeast extract: 5g, sodium acetate: 5g, diammonium hydrogen citrate: 2g, dipotassium hydrogen phosphate: 2g, MgSO4·7H2O:0.58g, MnSO4
H2O:0.25g, cysteine hydrochloride: 0.5g, Tween 80: 1ml, distilled water 1000mL.
5 Oxford cups are uniformly placed in empty plate, are poured into 2% agar of 10ml or so thereto, are made its solidification.Use LB
Culture medium cultivates Escherichia coli and salmonella respectively, its concentration is adjusted to 1 × 107~5 × 107CFU/mL.It takes respectively
The not solidified liquid agar medium of 20ml is added in 0.25ml Escherichia coli, salmonella suspension, pours into culture dish immediately,
Standing at room temperature makes its solidification.
Slowly Oxford cup is taken out, by the supernatant of the above-mentioned lactic acid bacteria culture supernatant stoste of 200 μ L and adjustment pH value
It is added in the cavity that Oxford cup leaves, and stands in an aseptic environment, so that supernatant is diffused into inside agar.Then aerobic
In 37 DEG C of culture 18h under environment, antibacterial circle diameter size is observed and measures, modified MRS culture medium is as negative control.
3, the measurement of acetaldehyde dehydrogenase ability is produced
Acetaldehyde-dehydrogenase enzymatic determination is measured using microplate reader, is operated according to ALDH kit specification.
Alcohol is oxidized to acetaldehyde by alcohol dehydrogenase first in vivo, then is oxidized to acetic acid by acetaldehyde dehydrogenase, and most
The acetaldehyde dehydrogenase of number people is insufficient, cannot be effectively by intracorporal oxidation of acetaldehyde, and acetaldehyde gathers in vivo, causes the more of body
Kind malaise symptoms.The lactobacillus plantarum LP45 has very strong generation acetaldehyde dehydrogenase ability, can be by the second in enteron aisle
Formoxy- turns to acetic acid, and then formation water and carbon dioxide excrete.
4, determination oxidative
(1) SOD and GSH is measured using microplate reader, is operated respectively according to SOD, GSH kit specification.
In the metabolic process of alcohol, a large amount of free radical can be generated, it is thin to Gastric Mucosal Cells, enterocyte, liver
Born of the same parents etc. cause to damage, and SOD and GSH can directly remove free radical, and lactobacillus plantarum LP45 can produce a large amount of SOD as the result is shown
With GSH enzyme activity, effectively removing DPPH, hydroxy radical, superoxide anion.
(2) to H2O2Tolerance: in 250ml triangular flask be added 150ml sterilizing MRS culture medium, add respectively
H2O2Solution makes the starting H in culture medium2O2Concentration is respectively 0.4 mmol/L, 0.7mmol/L, 1.0mmol/L, and presses volume
The inoculum concentration access 10 that score is 3%8Each bacterial strain bacteria suspension of CFU/mL, is placed in 37 DEG C of constant incubators and cultivates, every 2h takes
1 bacterium solution surveys its OD value with visible spectrophotometer, and culture for 24 hours, observes lactic acid bacteria in different starting H2O2Growth under concentration
Trend.
5, inhibit blood ammonia increase, is anti-oxidant, reduce serum endotoxin, inhibiting inflammatory factor, liver is strong after drinking for effective protection
Health
(1) foundation and grouping of animal model
SPF grades C57BL/6 healthy mice 40, male, adaptive feeding is randomly divided into 4 groups, every group 10 after a week.
Take stomach-filling mode twice a day: blank control group twice daily gavages physiological saline；Alcoholic liver injury model group, on
Noon stomach-filling alcohol, stomach-filling in afternoon physiological saline；Positive drug control group, morning stomach-filling alcohol, stomach-filling in afternoon liver-protecting tablet solution；It plants
Object lactobacillus LP45 intervention group, morning stomach-filling alcohol, stomach-filling in afternoon lactobacillus plantarum LP45 bacterium solution.
Alcohol concentration is gradually increased according to 20%-25%-30%-40%, and 40% (v/v) is increased in two weeks and is maintained afterwards
This concentration to experiment terminates；Drug is sunflower board liver-protecting tablet, according to dose lonvestion to mouse respective concentration；Lactobacillus plantarum LP45
Concentrated freeze-dried powder is made, is resuspended before each stomach-filling with physiological saline, adjustment concentration is respectively 1.0 × 109CFU/mL, in 37 DEG C of water
It is used after recovery 30min in bath.All samples carry out stomach-filling according to 10ml/kg BW, and test period is 3 months.Timing daily
Supplement drinking-water and feed replace weekly a padding, are observed continuously after the completion of stomach-filling to animal, record experimental animal in time
Poisoning manifestations and death condition, it is dissected when necessary and makees naked eyes pathological observation.
Fasting for 24 hours, plucks rapidly eyeball acquisition blood after last provisions, and solution takes the measurement items such as liver, different intestinal segments and refers to
Mark.
6, every biochemical indicator is detected
Contained by measuring the activity of serum transaminase of mouse, fat content, the oxidation index of liver, serum endotoxin
Amount, expression of inflammatory cytokine etc., and the pathological observation of hepatic tissue is carried out, to intervene lactobacillus plantarum LP45 chronic
The effect of alcoholic liver injury is assessed in vivo.
(1) preparation of mice serum and liver homogenate sample
Taken blood is centrifuged 15min in 4 DEG C of standings 1h, 2500rpm, careful collection upper transparent liquid is serum.
Serum uses immediately as far as possible after obtaining or cryopreservation is stand-by, generally requires in -20 DEG C~-70 DEG C cryopreservations, if storage
It is not exceeded then one month at 4 DEG C.
The liver of mouse after dissection is rinsed in ice-cold physiological saline wipe it is dry, weighing, tissue is shredded with eye scissors,
It pours into glass homogenate tube, the cold saline that 9 times of tissue block weight are added is fully ground, and makes liver tissue homogenate, will be prepared
10% good homogenate 3000rpm is centrifuged 15min, abandons precipitating, gained supernatant is liver cloud slurries, the storage conditions and blood of liver homogenate
It is clear identical.
(2) measurement of every biochemical indicator
The content of mice serum glutamic-oxalacetic transaminease (AST), glutamic-pyruvic transaminase (ALT), superoxide dismutase in liver homogenate
(SOD), the measurement of the concentration of glutathione (GSH) and malonaldehyde (MDA), bacterium are specific in strict accordance with corresponding reagent box specification
Operating procedure carries out；
The activity of serum transaminase ALT, AST are the most sensitive marks of hepatic injury caused by ethyl alcohol.Chronic Alcohol exposure causes
ALT activity and AST activity are significantly raised in mice serum, and lactobacillus plantarum LP45 can effectively restore ALT, AST after intervening
Activity.This is the result shows that selected lactobacillus plantarum LP45 is able to suppress the raising of Chronic Alcohol serum of hepatic injury transaminase.
MDA is considered as the important products and indicant of body lipid peroxidation, and GSH and SOD is in host's antioxygen chemoprevention
It plays an important role in imperial system, the reduction of the substance will lead to mitochondrial function damage, further result in active oxygen radical
(ROS) excessive increase, so as to cause oxidative damage.Oxidation index in mouse liver is analyzed, after Chronic Alcohol processing,
Compared with the control group, MDA concentration is significantly raised in alcohol model group mouse liver, and GSH content SOD activity significantly reduces.Phase
For model group, lactobacillus plantarum LP45 (YMC1005) processing can be effectively reduced MDA concentration, and restore GSH content
With SOD activity.This is the result shows that the lactobacillus plantarum LP45 (YMC1005) can effectively inhibit caused by Chronic Alcohol
Oxidative damage.
(3) serum endotoxin measures
The measurement of serum endotoxin uses enzyme-linked immunosorbent assay, is operated according to ELISA kit specification.
Endotoxin is lipopolysaccharides (LPS) ingredient on gram-negative bacterial cell wall outer membrane, has extensive biology living
Property, serious cascade of response of inflammation can be caused, be one of principal causative ingredient of Gram-negative bacteria.In existing research confirms
Toxin is the common material base of the hepatic injury of a variety of causes induction, can directly or indirectly cause the damage of liver.To small
LPS content is analyzed in mouse serum, it will be appreciated from fig. 6 that after Chronic Alcohol processing, LPS content in alcohol model group mice serum
Apparent increase, and LPS content is significantly reduced after the lactobacillus plantarum LP45 (YMC1005) intake.This result shows that institute
Lactobacillus plantarum LP45 (YMC1005) is selected to be able to suppress the raising of LPS content in serum caused by Chronic Alcohol.
(4) measurement of inflammatory factor expression
The expression of TNF-α, IL-6, IL-1 β etc. are detected using ELISA in liver.
Tumor necrosis factor-alpha (TNF-α), interleukin (Interleukin, IL) -1 β, IL-6 are generally considered body
The pro-inflammatory cytokine (proinflammatory cytokines, also known as pro-inflammatory cytokines) of tissue secretion.To small
TNF-α, IL-6, IL-1 β content obviously increase in mouse liver, and substantially reduce after lactobacillus plantarum LP45 (YMC1005) processing
TNF-α, the content of IL-6, IL-1 β.This result shows that selected lactobacillus plantarum LP45 (YMC1005) be able to suppress it is chronic
The raising of Inflammatory Factors Contents in liver caused by alcohol.
(5) liver histopathology is observed
After taking the tissue of mouse liver lobus sinister same position to be fixed with 10% formalin, by paraffin embedding, it is sliced, so
It is dyed afterwards with h and E dyestuff, observation is taken pictures under the microscope.
Chronic Alcohol exposure causes serious pathology damage to mouse liver.Blank group liver cell structure is more complete, liver
Cell has apparent boundary and endochylema is uniform, there is Minimal fatty cavity, no inflammatory infiltration；And modeling group steatosis is obvious, has
Large stretch of fat cavity, swelling of liver cell deformation have reticular structure, inflammatory cell infiltration occur；Lactobacillus plantarum LP45
(YMC1005) intervene and then effectively alleviate these pathology damages, show as fat bubble and reduce, mild inflammatory cell infiltration.
Two, Application Example
Application Example 1: relieving alcoholism and protecting liver instant type is manufactured using lactobacillus plantarum LP45 (YMC1005) of the present invention
Lactic acid bacteria powder.
Its viable count is set to reach 10 Lactobacillus helveticus of the invention9CFU/ml, with lactitol, oligofructose, stachyose
Equal prebiotics, which are matched, is combined into relieving alcoholism and protecting liver instant type lactic acid bacteria powder preparation.
Application Example 2: gained bacterium powder is lyophilized using lactobacillus plantarum LP45 of the present invention, viable count reaches
109CFU/ml is uniformly mixed with 100g mayonnaise, makes vegetable and fruit salad, for vegetable before wine, is eaten before wine, is alleviated wine
Malaise symptoms afterwards.
Application Example 3: it is fermented using lactobacillus plantarum LP45 (YMC1005) of the present invention production lactobacillus plantarum
Cream, specific method first mix milk, white granulated sugar, cream with stabilizer, homogeneous sterilization are carried out after material, by the plant
Object lactobacillus inoculation fermentation is sub-packed in 4 DEG C of after-ripening after demulsification, obtain the fermentation emulsion formulation for alleviating malaise symptoms after drinking, this
Preparation tart flavour, fragrance, viscosity, plumpness, sophistication, grease sense, smoothness are detailed in Figure 16.By the lactobacillus plantarum
LP45 acidified milk weighs 1g, and in the simulated gastric fluid that the pH value for being respectively placed in the processing of filtration sterilization containing 9ml is 3.0, concussion is uniform simultaneously
Cultivated at 37 DEG C, 0,1,2,3,4h it is separately sampled, measure its viable count.As a result prove lactobacillus plantarum LP45 in simulation hydrochloric acid
Under environment, survival rate has been more than 48.19% or more within 4h, has good acid resistance, sees Figure 17.Moreover, 3h with
Interior, the survival rate of lactobacillus plantarum LP45 (YMC1005) is on the rise, it was demonstrated that lactobacillus plantarum LP45 continues within this time
Growth.So this product is taken before can be used for wine, it is uncomfortable to alleviate body after drinking.
Lactobacillus plantarum of the present invention can alleviate a variety of malaise symptoms after drinking not only for relieving alcoholic liver injury,
By lactobacillus plantarum LP45 (YMC1005), bacterial strain itself generates acetaldehyde dehydrogenase and carrys out oxidizing acetaldehyde, becomes harmless for body
Acetic acid, while the glutathione peroxidase that bacterial strain itself generates can be effective against the oxygen for caused by body of drinking
Change damage.
Claims (6)
1. lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation.
2. application according to claim 1, which is characterized in that the lactobacillus plantarum LP45 access MRS in -80 DEG C will be frozen
In fluid nutrient medium, 37 DEG C of culture 18h, after continuously activating three generations, 6000rmp is centrifuged 10min at 4 DEG C, supernatant is abandoned, by thallus
With the brine of sterilizing three times after, be resuspended in physiological saline and adjust cell concentration 109It is outstanding to obtain cell by CFU/ml
Liquid, preservation is stand-by in 4 DEG C of low temperature, and by cell suspension by freeze-drying, lactobacillus plantarum LP45 pulvis is prepared.
3. application according to claim 2, which is characterized in that the food uses oligofructose, lactitol, stachyose
One of or any combination be mixed to get with lactobacillus plantarum LP45 pulvis.
4. application according to claim 2, which is characterized in that mixed with 100 grams of mayonnaise by lactobacillus plantarum LP45 pulvis
It closes uniformly, is made as vegetable and fruit salad, controls its viable count and reach 109CFU/ml。
5. according to application as claimed in claim 2, which is characterized in that be made as fermenting using lactobacillus plantarum LP45 as fermentation strain
Cream.
6. application according to claim 1, which is characterized in that the dosage form of the food is granule, pulvis or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910558717.0A CN110192654A (en) | 2019-06-26 | 2019-06-26 | Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910558717.0A CN110192654A (en) | 2019-06-26 | 2019-06-26 | Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110192654A true CN110192654A (en) | 2019-09-03 |
Family
ID=67755161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910558717.0A Pending CN110192654A (en) | 2019-06-26 | 2019-06-26 | Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110192654A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112143667A (en) * | 2020-09-07 | 2020-12-29 | 安徽农业大学 | Acid-resistant lactobacillus plantarum with high acetaldehyde dehydrogenase expression and application thereof |
| CN112868769A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Yogurt for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN114381398A (en) * | 2022-01-08 | 2022-04-22 | 浙江大学 | Lactobacillus helveticus ZJUIDS12 capable of improving alcoholic liver disease and application thereof |
| CN114507619A (en) * | 2022-01-28 | 2022-05-17 | 河北一然生物科技股份有限公司 | Liquid composite probiotic preparation, preparation method thereof and application thereof in aspects of improving diarrhea and protecting liver |
| CN114668783A (en) * | 2022-05-30 | 2022-06-28 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus plantarum strain WKA86 in preparing liver protection/antioxidation/prevention and treatment of alcoholic liver injury medicines |
| CN115710563A (en) * | 2022-09-26 | 2023-02-24 | 重庆第二师范学院 | Lactobacillus pentosus CQZC02 and application thereof in preparation of drugs for treating liver injury |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102618456A (en) * | 2012-02-28 | 2012-08-01 | 江南大学 | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof |
| CN102994422A (en) * | 2012-11-12 | 2013-03-27 | 北京和美科健生物技术有限责任公司 | Application of lactobacillus plantarum P-8 in improvement of alcoholic liver injury |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
| CN103642716A (en) * | 2013-11-21 | 2014-03-19 | 河北一然生物科技有限公司 | Lactobacillus plantarum and application thereof |
| CN103893215A (en) * | 2014-04-17 | 2014-07-02 | 扬州大学 | Application of lactobacillus casei grx12 in preparation of product for treating chronic alcoholic liver injury |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
-
2019
- 2019-06-26 CN CN201910558717.0A patent/CN110192654A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102618456A (en) * | 2012-02-28 | 2012-08-01 | 江南大学 | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof |
| US20140363501A1 (en) * | 2012-02-28 | 2014-12-11 | Jiangnan University | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
| CN102994422A (en) * | 2012-11-12 | 2013-03-27 | 北京和美科健生物技术有限责任公司 | Application of lactobacillus plantarum P-8 in improvement of alcoholic liver injury |
| CN103642716A (en) * | 2013-11-21 | 2014-03-19 | 河北一然生物科技有限公司 | Lactobacillus plantarum and application thereof |
| CN103893215A (en) * | 2014-04-17 | 2014-07-02 | 扬州大学 | Application of lactobacillus casei grx12 in preparation of product for treating chronic alcoholic liver injury |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112868769A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Yogurt for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN112143667A (en) * | 2020-09-07 | 2020-12-29 | 安徽农业大学 | Acid-resistant lactobacillus plantarum with high acetaldehyde dehydrogenase expression and application thereof |
| CN112143667B (en) * | 2020-09-07 | 2021-08-20 | 安徽农业大学 | Acid-resistant lactobacillus plantarum with high acetaldehyde dehydrogenase expression and application thereof |
| CN114381398A (en) * | 2022-01-08 | 2022-04-22 | 浙江大学 | Lactobacillus helveticus ZJUIDS12 capable of improving alcoholic liver disease and application thereof |
| CN114381398B (en) * | 2022-01-08 | 2022-06-14 | 浙江大学 | Lactobacillus helveticus ZJUIDS12 capable of improving alcoholic liver disease and application thereof |
| CN114507619A (en) * | 2022-01-28 | 2022-05-17 | 河北一然生物科技股份有限公司 | Liquid composite probiotic preparation, preparation method thereof and application thereof in aspects of improving diarrhea and protecting liver |
| CN114507619B (en) * | 2022-01-28 | 2024-01-12 | 河北一然生物科技股份有限公司 | Liquid composite probiotic preparation, preparation method thereof and application thereof in aspects of improving diarrhea and protecting liver |
| CN114668783A (en) * | 2022-05-30 | 2022-06-28 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus plantarum strain WKA86 in preparing liver protection/antioxidation/prevention and treatment of alcoholic liver injury medicines |
| CN115710563A (en) * | 2022-09-26 | 2023-02-24 | 重庆第二师范学院 | Lactobacillus pentosus CQZC02 and application thereof in preparation of drugs for treating liver injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110192654A (en) | Lactobacillus plantarum LP45 alleviates the application in the food of body injury after drinking in preparation | |
| CN110893195B (en) | Lactobacillus paracasei ET-22 with function of relieving intestinal inflammation | |
| CN110016442B (en) | Application of lactobacillus rhamnosus and compound bacterium powder thereof in product for preventing and treating vaginitis | |
| CN110835616B (en) | Active substance of lactobacillus paracasei GKS6, composition containing same and application of active substance in promoting longevity | |
| CN1856568B (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN110241046A (en) | A kind of Lactobacillus helveticus that capableing of relieving alcoholic liver injury and application | |
| CN110892940A (en) | New application of lactobacillus paracasei K56 in relieving intestinal inflammation | |
| CN110272842A (en) | One plant of lactobacillus plantarum LP104 with fat reducing and weight reducing function | |
| JP7492584B2 (en) | Novel use of Bifidobacterium lactis BL-99 in suppressing intestinal inflammation | |
| CN107058158A (en) | A kind of dog immunity that improves reduces the compound probiotic agent and its preparation and application of diarrhea disease percentage | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN102174450B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof | |
| JP2017509636A (en) | Composition comprising post-fermented tea extract | |
| CN104430851A (en) | Fermented milk capable of reducing cholesterol and preparation method of fermented milk | |
| KR102139687B1 (en) | Lactobacillus MG4288 for the treatment or improvement of vaginitis with antimicrobial effect on Gardnerella vaginalis and Candida albicans | |
| CN109259146A (en) | One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application | |
| JP2018153182A (en) | Lactobacillus plantarum tci378, and use thereof in reducing fat and improving gastrointestinal function | |
| CN103937716A (en) | Anthropogenic lactobacilus fermentum grx07 and application thereof | |
| CN106413724A (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
| CN114191464B (en) | Traditional Chinese medicine microecological preparation for improving duck growth performance and application thereof | |
| CN115322932A (en) | Lactobacillus plantarum with capacity of dispelling effects of alcohol and sobering up and application thereof | |
| CN108295096A (en) | Application of the bacterial strain in prevention and treatment mycotic, bacterial vaginitis preparation | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN107412272A (en) | Application of the Lactobacillus plantarum in gut barrier injury is prevented | |
| CN106119139A (en) | A kind of selenium-rich produces glutathion compound bacteria and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: No.16, bangxiu East Road, North District, Zhengding high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |